Moxifloxacin Kabi (Moxifloxacin Hydrochloride)

Moxifloxacin Kabi is a fluoroquinolone antibacterial indicated for several serious bacterial infections.

• Community‑acquired bacterial pneumonia: provides rapid bactericidal activity to resolve pulmonary infection and improve respiratory function.
• Complicated intra‑abdominal infections: achieves broad‑spectrum coverage of aerobic and anaerobic pathogens involved in intra‑abdominal sepsis.
• Complicated skin and soft tissue infections: eliminates resistant Gram‑positive and Gram‑negative organisms to promote wound healing.
• Acute bacterial sinusitis: eradicates the causative bacteria, relieving sinus inflammation and congestion.

• Moxifloxacin Hydrochloride inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA supercoiling and replication. By blocking these targets, the drug prevents bacterial DNA synthesis and transcription, leading to rapid bactericidal activity against susceptible Gram‑positive and Gram‑negative organisms.

Moxifloxacin Kabi may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: often self‑limiting, may be watery.
• Headache: transient and usually resolves without intervention.
• Injection site reactions: erythema or discomfort at the infusion site.

Serious or Rare Side Effects

• Tendon rupture or tendinitis: especially in the Achilles tendon, may occur during or after therapy.
• QT interval prolongation: can precipitate ventricular arrhythmias, particularly in patients with cardiac risk factors.
• Severe hypersensitivity reactions: including anaphylaxis, Stevens‑Johnson syndrome, or toxic epidermal necrolysis.

Before initiating therapy, clinicians should consider several safety aspects.

• Renal impairment: monitor renal function and adjust therapy as needed.
• History of tendon disorders: avoid use in patients with prior tendon injury or tendon‑related conditions.
• QT prolongation risk: obtain baseline ECG and avoid concomitant QT‑prolonging agents.
• Concurrent use with antacids containing aluminum or magnesium: separate administration by at least 2 hours to prevent reduced absorption.
• Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Moxifloxacin Kabi can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

• Co‑administration with other fluoroquinolones: increased risk of additive toxicity.
• Concurrent use with drugs that prolong the QT interval (e.g., macrolides, antiarrhythmics): heightened risk of cardiac arrhythmias.
• Combination with non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase the likelihood of central nervous system adverse effects.

Moderate Interactions (Monitor Closely)

• Antacids or supplements containing divalent cations (calcium, iron, magnesium, zinc): may reduce drug absorption; separate dosing by at least 2 hours.
• Warfarin: may enhance anticoagulant effect; monitor INR closely.
• Theophylline: possible increase in serum theophylline levels; observe for signs of toxicity.